01.02.2016 - The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to UK-Swedish drug maker AstraZeneca for its oral poly ADP-ribose polymerase (PARP)...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)